Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment

Sudeepa Bhattacharyya, Boadie W. Dunlop, Siamak Mahmoudiandehkordi, Ahmed T. Ahmed, Gregory Louie, Mark A. Frye, Richard M. Weinshilboum, Ranga R. Krishnan, A. John Rush, Helen S. Mayberg, W. Edward Craighead, Rima Kaddurah-Daouk

Research output: Contribution to journalArticle

Abstract

Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect and relate closely to the severity of depressive symptoms, so-called “state-dependent” biomarkers of depression, this pilot study explored the biochemical underpinnings of treatment response to cognitive behavior therapy (CBT) in medication-free MDD outpatients. Plasma samples were collected at baseline and week 12 from a subset of MDD patients (N = 26) who completed a course of CBT treatment as part of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Targeted metabolomic profiling using the AbsoluteIDQ® p180 Kit and LC-MS identified eight “co-expressed” metabolomic modules. Of these eight, three were significantly associated with change in depressive symptoms over the course of the 12-weeks. Metabolites found to be most strongly correlated with change in depressive symptoms were branched chain amino acids, acylcarnitines, methionine sulfoxide, and α-aminoadipic acid (negative correlations with symptom change) as well as several lipids, particularly the phosphatidlylcholines (positive correlation). These results implicate disturbed bioenergetics as an important state marker in the pathobiology of MDD. Exploratory analyses contrasting remitters to CBT versus those who failed the treatment further suggest these metabolites may serve as mediators of recovery during CBT treatment. Larger studies examining metabolomic change patterns in patients treated with pharmacotherapy or psychotherapy will be necessary to elucidate the biological underpinnings of MDD and the -specific biologies of treatment response.

Original languageEnglish (US)
Article number926
JournalFrontiers in Neuroscience
Volume13
DOIs
StatePublished - Sep 12 2019

Fingerprint

Metabolomics
Cognitive Therapy
Major Depressive Disorder
Depression
Therapeutics
Branched Chain Amino Acids
Psychotherapy
Energy Metabolism
Signs and Symptoms
Outpatients
Biomarkers
Lipids
Drug Therapy
Acids

Keywords

  • acylcarnitines
  • branched-chain amino acids
  • cognitive behavioral therapy
  • lipids
  • major depression
  • metabolomics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Bhattacharyya, S., Dunlop, B. W., Mahmoudiandehkordi, S., Ahmed, A. T., Louie, G., Frye, M. A., ... Kaddurah-Daouk, R. (2019). Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Frontiers in Neuroscience, 13, [926]. https://doi.org/10.3389/fnins.2019.00926

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. / Bhattacharyya, Sudeepa; Dunlop, Boadie W.; Mahmoudiandehkordi, Siamak; Ahmed, Ahmed T.; Louie, Gregory; Frye, Mark A.; Weinshilboum, Richard M.; Krishnan, Ranga R.; Rush, A. John; Mayberg, Helen S.; Craighead, W. Edward; Kaddurah-Daouk, Rima.

In: Frontiers in Neuroscience, Vol. 13, 926, 12.09.2019.

Research output: Contribution to journalArticle

Bhattacharyya, S, Dunlop, BW, Mahmoudiandehkordi, S, Ahmed, AT, Louie, G, Frye, MA, Weinshilboum, RM, Krishnan, RR, Rush, AJ, Mayberg, HS, Craighead, WE & Kaddurah-Daouk, R 2019, 'Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment', Frontiers in Neuroscience, vol. 13, 926. https://doi.org/10.3389/fnins.2019.00926
Bhattacharyya, Sudeepa ; Dunlop, Boadie W. ; Mahmoudiandehkordi, Siamak ; Ahmed, Ahmed T. ; Louie, Gregory ; Frye, Mark A. ; Weinshilboum, Richard M. ; Krishnan, Ranga R. ; Rush, A. John ; Mayberg, Helen S. ; Craighead, W. Edward ; Kaddurah-Daouk, Rima. / Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. In: Frontiers in Neuroscience. 2019 ; Vol. 13.
@article{5b8b4a34d6c345c492a8134a372d9cac,
title = "Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment",
abstract = "Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect and relate closely to the severity of depressive symptoms, so-called “state-dependent” biomarkers of depression, this pilot study explored the biochemical underpinnings of treatment response to cognitive behavior therapy (CBT) in medication-free MDD outpatients. Plasma samples were collected at baseline and week 12 from a subset of MDD patients (N = 26) who completed a course of CBT treatment as part of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Targeted metabolomic profiling using the AbsoluteIDQ{\circledR} p180 Kit and LC-MS identified eight “co-expressed” metabolomic modules. Of these eight, three were significantly associated with change in depressive symptoms over the course of the 12-weeks. Metabolites found to be most strongly correlated with change in depressive symptoms were branched chain amino acids, acylcarnitines, methionine sulfoxide, and α-aminoadipic acid (negative correlations with symptom change) as well as several lipids, particularly the phosphatidlylcholines (positive correlation). These results implicate disturbed bioenergetics as an important state marker in the pathobiology of MDD. Exploratory analyses contrasting remitters to CBT versus those who failed the treatment further suggest these metabolites may serve as mediators of recovery during CBT treatment. Larger studies examining metabolomic change patterns in patients treated with pharmacotherapy or psychotherapy will be necessary to elucidate the biological underpinnings of MDD and the -specific biologies of treatment response.",
keywords = "acylcarnitines, branched-chain amino acids, cognitive behavioral therapy, lipids, major depression, metabolomics",
author = "Sudeepa Bhattacharyya and Dunlop, {Boadie W.} and Siamak Mahmoudiandehkordi and Ahmed, {Ahmed T.} and Gregory Louie and Frye, {Mark A.} and Weinshilboum, {Richard M.} and Krishnan, {Ranga R.} and Rush, {A. John} and Mayberg, {Helen S.} and Craighead, {W. Edward} and Rima Kaddurah-Daouk",
year = "2019",
month = "9",
day = "12",
doi = "10.3389/fnins.2019.00926",
language = "English (US)",
volume = "13",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment

AU - Bhattacharyya, Sudeepa

AU - Dunlop, Boadie W.

AU - Mahmoudiandehkordi, Siamak

AU - Ahmed, Ahmed T.

AU - Louie, Gregory

AU - Frye, Mark A.

AU - Weinshilboum, Richard M.

AU - Krishnan, Ranga R.

AU - Rush, A. John

AU - Mayberg, Helen S.

AU - Craighead, W. Edward

AU - Kaddurah-Daouk, Rima

PY - 2019/9/12

Y1 - 2019/9/12

N2 - Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect and relate closely to the severity of depressive symptoms, so-called “state-dependent” biomarkers of depression, this pilot study explored the biochemical underpinnings of treatment response to cognitive behavior therapy (CBT) in medication-free MDD outpatients. Plasma samples were collected at baseline and week 12 from a subset of MDD patients (N = 26) who completed a course of CBT treatment as part of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Targeted metabolomic profiling using the AbsoluteIDQ® p180 Kit and LC-MS identified eight “co-expressed” metabolomic modules. Of these eight, three were significantly associated with change in depressive symptoms over the course of the 12-weeks. Metabolites found to be most strongly correlated with change in depressive symptoms were branched chain amino acids, acylcarnitines, methionine sulfoxide, and α-aminoadipic acid (negative correlations with symptom change) as well as several lipids, particularly the phosphatidlylcholines (positive correlation). These results implicate disturbed bioenergetics as an important state marker in the pathobiology of MDD. Exploratory analyses contrasting remitters to CBT versus those who failed the treatment further suggest these metabolites may serve as mediators of recovery during CBT treatment. Larger studies examining metabolomic change patterns in patients treated with pharmacotherapy or psychotherapy will be necessary to elucidate the biological underpinnings of MDD and the -specific biologies of treatment response.

AB - Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect and relate closely to the severity of depressive symptoms, so-called “state-dependent” biomarkers of depression, this pilot study explored the biochemical underpinnings of treatment response to cognitive behavior therapy (CBT) in medication-free MDD outpatients. Plasma samples were collected at baseline and week 12 from a subset of MDD patients (N = 26) who completed a course of CBT treatment as part of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Targeted metabolomic profiling using the AbsoluteIDQ® p180 Kit and LC-MS identified eight “co-expressed” metabolomic modules. Of these eight, three were significantly associated with change in depressive symptoms over the course of the 12-weeks. Metabolites found to be most strongly correlated with change in depressive symptoms were branched chain amino acids, acylcarnitines, methionine sulfoxide, and α-aminoadipic acid (negative correlations with symptom change) as well as several lipids, particularly the phosphatidlylcholines (positive correlation). These results implicate disturbed bioenergetics as an important state marker in the pathobiology of MDD. Exploratory analyses contrasting remitters to CBT versus those who failed the treatment further suggest these metabolites may serve as mediators of recovery during CBT treatment. Larger studies examining metabolomic change patterns in patients treated with pharmacotherapy or psychotherapy will be necessary to elucidate the biological underpinnings of MDD and the -specific biologies of treatment response.

KW - acylcarnitines

KW - branched-chain amino acids

KW - cognitive behavioral therapy

KW - lipids

KW - major depression

KW - metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85072831117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072831117&partnerID=8YFLogxK

U2 - 10.3389/fnins.2019.00926

DO - 10.3389/fnins.2019.00926

M3 - Article

AN - SCOPUS:85072831117

VL - 13

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

M1 - 926

ER -